https://www.selleckchem.com/pr....oducts/bismuth-subni
Donor's CYP3A-status (CYP3A5 genotype and CYP3A4 expression) can provide prognostic information regarding tacrolimus-metabolizing capacity of the liver graft and initial tacrolimus dosing for therapeutic blood concentrations in liver transplants. The present work prospectively investigated whether CYP3A-status guided tacrolimus therapy has any potential clinical benefit for recipients in the early postoperative period. The contribution of preliminary assaying of donor CYP3A-status to the optimization of initial tacrolimus the
Like
Comment
Share
